NCT05630001 - Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2023

Primary Completion Date

October 17, 2024

Study Completion Date

October 17, 2024

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG

Iptacopan

Treatment with iptacopan at a dose of 200 mg b.i.d. will start on the first day (Day 1) and continue for 24 weeks.

Trial Locations (23)

10461

Montefiore Medical Center, The Bronx

29615

Prisma Health Upstate, Greenville

33014

Lakes Research, Miami Lakes

34093

Novartis Investigative Site, Istanbul

36061

Novartis Investigative Site, Bassano del Grappa

44093

Novartis Investigative Site, Nantes

44195

Cleveland Clinic Foundation, Cleveland

45147

Novartis Investigative Site, Essen

50134

Novartis Investigative Site, Florence

52074

Novartis Investigative Site, Aachen

55455

University Of Minnesota, Minneapolis

75475

Novartis Investigative Site, Paris

89081

Novartis Investigative Site, Ulm

90033

USC Norris Cancer Center, Los Angeles

91010

City Of Hope National Med Center, Duarte

02114

Mass Gen Hosp Cancer Center, Boston

84112 0550

Huntsman Cancer Institute Univ of Utah, Salt Lake City

06202

Novartis Investigative Site, Nice

01307

Novartis Investigative Site, Dresden

06351

Novartis Investigative Site, Seoul

08036

Novartis Investigative Site, Barcelona

LS9 7TF

Novartis Investigative Site, Leeds

SE5 9RS

Novartis Investigative Site, London